EMA Recommends Extending Indications for Lisocabtagene Maraleucel By Ogkologos - November 12, 2025 221 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Pembrolizumab Combined with Chemoradiotherapy Improves PFS in Women with Newly Diagnosed,... March 27, 2024 How People With Advanced Cancer Can Find Meaning Toward the End... July 25, 2023 18-Year-Old Jaguar at Akron Zoo Diagnosed with Breast Cancer September 6, 2019 CAR T-Cell Therapy Approved by FDA for Mantle Cell Lymphoma August 24, 2020 Load more HOT NEWS Zero Mutation ctDNA Triage for Selection of Patients with Metastatic Colorectal... Can Targeted Therapy for KRAS Mutations Double as Part of Immunotherapy? Η ΚΑΘΗΜΕΡΙΝΟΤΗΤΑ NCI Expands Repository of Cancer Research Models: A Conversation with Drs....
